



Anti-microbial Activity of Metabolites Isolated from Fungi

Guest Editors:

Dr. Marco Clericuzio

Dipartimento di Scienze e
Innovazione Tecnologica DISIT,
Amedeo Avogadro University of
Eastern Piedmont, Vercelli, Italy

Dr. Elisa Gamalero

Department of Sciences and
Technological Innovation,
University of Piemonte Orientale,
viale T. Michel, 11-15121
Alessandria, Italy

Dr. Elisa Bona

Dipartimento per lo Sviluppo
Sostenibile e la Transizione
Ecologica, Università del
Piemonte Orientale, 13100
Vercelli, Italy

Deadline for manuscript
submissions:
closed (20 October 2024)

Message from the Guest Editors

Fungi are a noteworthy source of bioactive metabolites, but differently from plants, their metabolite contents have been much less investigated to this purpose. Several new molecules have been discovered in the past few years, but what is still missing is a systematic study of the active molecules synthesized by many taxonomic units. For instance, some genera belonging to phylum Basidiomycota, such as *Cortinarius*, *Entoloma*, *Russula*, *Mycena*, and *Inocybe*, have been only minimally investigated.

The inhibition of bacterial growth is a prominent property of several fungal compounds. Since the discovery of penicillin, more than 150 different antibiotics have been isolated and used for human therapy. However, bacteria developed resistance against most of these molecules, so that antimicrobial resistance is now one of the most concerning global threats for human health.

This Special Issue will address studies that focus on fungal metabolites from both mycelial broth culture and fruiting bodies, with a specific potential application for their antibiotic activity against bacterial and fungal human pathogens.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi